Over 25 companies advance tau inhibitors for Alzheimer's treatment, report shows
Summary: A new report from DelveInsight highlights over 25 companies developing tau inhibitors for Alzheimer's and related disorders. This surge in research is driven by an aging population and increased funding for neurodegenerative disease treatments.
Key players like TauRx Therapeutics and Ionis Pharmaceuticals are advancing various tau-targeting drugs through clinical trials. Recent developments include positive interim results from Alterity Therapeutics and Fast Track designation for AC Immune's candidate from the FDA.
The report outlines a robust pipeline of tau inhibitors, with innovative therapies aimed at preventing tau protein aggregation. These advancements could significantly impact treatment options for patients with tau-related neurodegenerative diseases.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings